AI Transparency Report
Regenmed Development Organization demonstrates a consistent operational pattern, with expenses closely tracking revenue across most recent filings. For instance, in 2023, expenses were $1,183,238 against revenues of $1,168,019, indicating a slight deficit. This trend of near break-even operations suggests careful financial management, though it also means limited surplus for future growth or reserves. The organization's assets have fluctuated, reaching a high of $3,311,743 in 2019 before declining to $565,309 in 2023, which warrants closer examination of asset management and investment strategies. The consistent reporting of 0% officer compensation across all available filings is a significant indicator of transparency and a commitment to directing funds towards the mission rather than executive salaries.
The organization's financial health appears stable but not robust, with liabilities often closely mirroring assets, as seen in 2023 where assets were $565,309 and liabilities were $600,696. This suggests a reliance on current funding for current operations without significant accumulation of unrestricted net assets. The NTEE code H12 (Medical Research) implies a focus on program services, and the absence of officer compensation strongly supports the idea that resources are being channeled effectively. However, without a detailed breakdown of program, administrative, and fundraising expenses, a precise assessment of spending efficiency is challenging.
Overall, Regenmed Development Organization exhibits strong transparency regarding executive compensation. Its financial operations are consistent, but the fluctuating asset base and close alignment of expenses to revenue suggest a need for strategic planning to build stronger financial reserves. The organization's commitment to its mission is evident through its compensation practices, but further detail on expense allocation would enhance the understanding of its spending efficiency.